Skip to main content

3M Needs To Take Firm Decision To Resolve Earplug Lawsuit

3M Needs To Take Firm Decision To Resolve Earplug Lawsuit

3M Needs To Take Firm Decision To Resolve Earplug Lawsuit

Introduction

3M Co. failed a bankruptcy court gambit to resolve almost 230,000 military earplug defect complaints and is now finding another road through mass tort litigation, one that includes a combination of trials, appeals, and settlements which would require the company to make difficult decisions, particularly about scheduling.

It is under pressure to address the massive backlog of veterans' hearing loss and tinnitus claims, yet it has appeals pending. More trials beyond the 16 already held might either assist or damage its settlement position. The stakes in the multidistrict action, as well as on appeal, could not be higher.

On Aug. 26, shares of the firm, which also sells Scotch-brand tape, Post-It notes, and NexCare bandages, plummeted 9% after a federal bankruptcy court refused to suspend the multidistrict earplug case. 3M attempted to reroute the claims through its company Aearo Technologies, which designed the Combat Arms version 2 earplugs.

Since then, 3M's stock has dropped more than 14%, closing at $110.50 a share on September 30, down from a 12-month high of $186.30 on November 12, 2021.

Analysts have struggled to put a price tag on 3M's possible earplug risk. In February, intelligence assessed that the stock's price relative to its industrial rivals reflected a $33 billion discount due to earplugs and a PFAS mass torts litigation in which it is also involved.

An analyst testifying for some of the veterans in the Aearo bankruptcy stated in August that 3M's earplug losses may be more than $100 billion, a number 3M rejected as faulty and unsubstantiated.

Whatever the figure, the potential liabilities are substantial, forcing the corporation to exploit whatever power it has in upcoming trials and unresolved appeals in order to find a way ahead.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

NC to Get $150M to Boost Opioid Treatment, Recovery

Categories: Opioids

North Carolina will receive an additional $150 million from Purdue Pharma and the Sackler family as part of a national $7.4 billion settlement related to the opioid

SRI Gets FDA OK for High-Dose Naloxone Trial

Categories: Opioids

SRI has received authorization from the U.S. Food and Drug Administration (FDA) to begin Phase 1 clinical trials of a new, high-dose injectable naloxone formulation.

The approval was granted under an Investigational New Drug (IND)…

Spokane County to Get $5M in New Opioid Settlement

Categories: Opioids

Jurisdictions within Spokane County are set to receive nearly $4.7 million as part of a sweeping $7.4 billion nationwide settlement with Purdue Pharma and its owners, the Sackler family.

The agreement addresses the company’s role in fueling…

✍️ FREE—3000 Pages Medical Record Review Trial!                
No Contract. No Risk—Fully Customized, Free!

Only 10 Firms Accepted—Offer Ends June 30!